OZEM
Roundhill GLP-1 & Weight Loss ETF
NAV as of
4 Week: 29.79 - 31.76
52 Week: 23.47 - 37.01
Latest Closing Price
30.56
Premium / Discount
0.06
Expense Ratio
0.59%
Investment Objective
The investment seeks to provide capital appreciation. The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -10.53 | 1.49 | -7.05 |
| 1 Day | -0.95 | 0.00 | 0.00 |
| 1 Week | 0.32 | 4.65 | 0.07 |
| 1 Month | -3.61 | 7.27 | -0.50 |
| 3 Months | -3.25 | 11.25 | -0.29 |
| 6 Months | -11.42 | 16.48 | -0.69 |
| 1 Year | 10.36 | 23.89 | 0.43 |
| 2 Years | 17.63 | 35.21 | 0.50 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 41.3582 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 8.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 29/12/2025 | 30/12/2025 | 0.4099 |
| 29/12/2024 | 30/12/2024 | 0.0531 |
Portfolio Data
Total Number of Holdings: 27
Number of Bond Holdings: 0
Number of Equity Holdings: 25
Total Market Value: 47,632,596
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Eli Lilly and Co | 19.7870 | 8,247 | 0 | 9,371,643 |
| 2 | Novo Nordisk AS ADR | 13.0549 | 144,433 | 0 | 6,183,177 |
| 3 | Pfizer Inc | 6.6266 | 122,599 | 0 | 3,138,534 |
| 4 | CSPC Pharmaceutical Group Ltd | 4.6159 | 2,360,000 | 0 | 2,186,217 |
| 5 | Viking Therapeutics Inc | 4.3085 | 73,536 | 0 | 2,040,624 |
| 6 | Chugai Pharmaceutical Co Ltd | 4.3064 | 43,300 | 0 | 2,039,615 |
| 7 | Kailera Therapeutics Inc | 3.9192 | 96,982 | 0 | 1,856,235 |
| 8 | Zealand Pharma AS | 3.7866 | 40,944 | 0 | 1,793,436 |
| 9 | Innovent Biologics Inc | 3.7757 | 188,500 | 0 | 1,788,286 |
| 10 | Amgen Inc | 3.7572 | 5,269 | 0 | 1,779,499 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 43.43 |
| Large | 21.57 |
| Medium | 15.43 |
| Small | 8.12 |
| Micro | 8.24 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
11.8875
Price/Book*
3.3664
Price/Sales*
0.9733
Price/Cash Flow*
9.7492
Dividend Yield*
2.1643
Growth Measures
Long-Term Earnings
4.5332
Historical Earnings
8.1620
Sales Growth
15.1176
Cash-Flow Growth
19.6936
Book-Value Growth
13.4437
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
